Neoplasms, Germ Cell and Embryonal
Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.
Subtype terms (9)
More specific conditions that are subtypes of Neoplasms, Germ Cell and Embryonal in the MeSH hierarchy.
- Carcinoma, Embryonal
7 drugs approved
- Chordoma
42 drugs (28 approved, 14 experimental)
- Germinoma
20 drugs (18 approved, 2 experimental)
- Gonadoblastoma
- Mesonephroma
- Neuroectodermal Tumors
79 drugs (48 approved, 31 experimental)
- Teratocarcinoma
1 drug approved
- Teratoma
20 drugs (16 approved, 4 experimental)
- Trophoblastic Neoplasms
2 drugs approved
Drugs by status
Phase 4 trials (9)
Phase 3 trials (15)
Phase 2 trials (71)
- mannitol
- thalidomide
- azacitidine
- ly-3023414
- avelumab
- mk-1775
- olaparib
- talazoparib
- brentuximab vedotin
- bvd-523
- irinotecan
- eflornithine
- disulfiram
- selinexor
- doxorubicin
- durvalumab
- erdafitinib
- fluorouracil
- palonosetron
- epirubicin
- nivolumab
- larotrectinib
- memantine
- alisertib
- olanzapine
- palbociclib
- pazopanib
- zarnestra
- sunitinib
- thrombopoietin
- +41 more
Phase 1 trials (51)
- simvastatin
- 19-28z t cells
- decitabine
- urea
- blu-667
- busulfan
- lenalidomide
- cilengitide
- ef5
- g207
- tacrolimus
- trametinib
- guadecitabine
- hydrocortisone
- bc8
- ispinesib
- keyhole limpet hemocyanin
- ribociclib
- o6-benzylguanine
- ro4929097
- celecoxib
- sgt-53
- mycophenolate
- sonidegib
- tetrahydrouridine
- alemtuzumab
- Anti-thymocyte Globulin (Rabbit)
- bortezomib
- veliparib
- vorinostat
- +21 more
Other trials (2)
Organizations
Organization Involved with Phase 4 Indications (6)
Organization Involved with Phase 3 Indications (42)
- Merck
- Blueprint Medicines Corporation
- Medical Research Council
- National Cancer Institute (NCI)
- Huazhong University of Science and Technology
- Aarhus University
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- Cancer and Leukemia Group B (CALGB)
- Cancer Research Campaign
- Cancer Research UK
- Cancer Trials Ireland
- Children's Cancer and Leukaemia Group
- University of London
- Cornell University
- Harvard University
- Eastern Cooperative Oncology Group
- Hoosier Cancer Research Network
- Indiana University
- Oregon Health and Science University
- Southwest Oncology Group
- UNICANCER
- University of Melbourne
- University of Sydney
- University of Birmingham
- University of California, San Francisco
- University of Cambridge
- University of Copenhagen
- Zhejiang University
- Shandong University
- Royal Marsden Hospital NHS Trust
- +12 more
Organization Involved with Phase 2 Indications (58)
- Daiichi Sankyo
- Millennium Pharmaceuticals
- Bristol-Myers Squibb
- Astellas
- AstraZeneca
- Genentech
- Merck KGaA
- Pfizer
- Sanofi
- Novartis
- GlaxoSmithKline
- Tesaro
- Ziopharm
- Fondazione Michelangelo
- National Institutes of Health (NIH)
- British Columbia Cancer Agency
- National Cancer Institute, France
- National Cancer Institute, Slovakia
- National Institute of Neurological Disorders and Stroke (NINDS)
- Velindre NHS Trust
- University of Pennsylvania
- Ajou University
- University of Pittsburgh
- Baylor University
- Canadian Urologic Oncology Group
- Case Western Reserve University
- Cancer Treatment Centers of America
- Centre Leon Berard
- Duke University
- Temple University
- +28 more
Organization Involved with Phase 1 Indications (11)
Organization Involved with Other Experimental Indications (4)